Bentovim Lyron L
Transaction: 11/19/2025
BUY
Change
+1,757
Price
$4.52
Filing
11/19/2025
Type
BUY
Manhattan Bridge Capital, Inc.
LOAN • REIT - Mortgage
$4.08
▼ -0.02 (-0.49%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$46.86M
Growth
-3.6%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 58.9%Positive free cash flow · 430.9Consistent free cash flow · 5/5Reasonable earnings multiple · 10.41Manageable debt level · 0.41
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$4.08
Change-0.49%
Market Cap$46.86M
52W Range4.10 - 5.80
Beta0.12
Gross Margin79.78%
Oper. Margin58.89%
Profit Margin58.88%
Debt/Eq0.41
Current Ratio30.71
Quick Ratio30.71
Revenue 5Y-3.58%
Price$4.08
Change-0.49%
Market Cap$46.86M
52W Range4.10 - 5.80
Beta0.12
Gross Margin79.78%
Oper. Margin58.89%
Profit Margin58.88%
Debt/Eq0.41
Current Ratio30.71
Quick Ratio30.71
Revenue 5Y-3.58%
FCF 5Y31.06%
Volume53.61K
Avg Volume32.05K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
85
out of 100
Business Quality
Margins, moat, returns
85/100
Financial Strength
Debt, cash, stability
78/100
Growth Potential
Revenue and expansion
78/100
Price Attractiveness
Cheap or expensive today
82/100
Why this score▼
Stable or improving margins · 58.9%Positive free cash flow · 430.9Consistent free cash flow · 5/5Reasonable earnings multiple · 10.41Manageable debt level · 0.41Healthy liquidity · 30.71
Analyst view
No analyst data available now.
Insider Transactions
Recent executive and insider activity
RAN ASSAF
Transaction: 11/17/2025
BUY
Change
+4,000
Price
$4.65
Filing
11/18/2025
Type
BUY
RAN ASSAF
Transaction: 05/12/2023
BUY
Change
+5,000
Price
$4.94
Filing
05/12/2023
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Bentovim Lyron L | BUY | +1,757 | $4.52 | 11/19/2025 | 11/19/2025 |
| RAN ASSAF | BUY | +4,000 | $4.65 | 11/17/2025 | 11/18/2025 |
| RAN ASSAF | BUY | +5,000 | $4.94 | 05/12/2023 | 05/12/2023 |
| RAN ASSAF | BUY | +319 | $5.05 | 04/26/2023 | 04/26/2023 |
| RAN ASSAF | BUY | +1,721 | $5.00 | 04/25/2023 | 04/26/2023 |
| RAN ASSAF | BUY | +5,000 | $5.01 | 04/24/2023 | 04/24/2023 |
| RAN ASSAF | BUY | +8,000 | $5.42 | 10/21/2022 | 10/25/2022 |
| JACKSON MICHAEL | BUY | +1,344 | $5.35 | 06/16/2022 | 06/17/2022 |
| JACKSON MICHAEL | BUY | +2,000 | $5.40 | 05/23/2022 | 05/24/2022 |
| JACKSON MICHAEL | BUY | +2,000 | $5.36 | 05/20/2022 | 05/23/2022 |
| RAN ASSAF | BUY | +5,000 | $5.71 | 12/30/2021 | 01/03/2022 |
| Bentovim Lyron L | SELL | -31,887 | $4.19 | 10/22/2020 | 10/22/2020 |
| RAN ASSAF | BUY | +7,500 | $4.04 | 09/14/2020 | 09/14/2020 |
| RAN ASSAF | BUY | +7,500 | $3.87 | 03/30/2020 | 03/31/2020 |
| RAN ASSAF | BUY | +7,500 | $2.65 | 03/25/2020 | 03/30/2020 |
| RAN ASSAF | BUY | +7,500 | $3.05 | 03/25/2020 | 03/25/2020 |
| RAN ASSAF | BUY | +6,500 | $3.47 | 03/24/2020 | 03/24/2020 |
| RAN ASSAF | BUY | +8,000 | $3.63 | 03/20/2020 | 03/20/2020 |
| RAN ASSAF | BUY | +7,000 | $3.97 | 03/18/2020 | 03/18/2020 |
| Kao Vanessa | BUY | +3,000 | $3.25 | 03/18/2020 | 03/18/2020 |